-
THURSDAY! MOASC’s Targeted Oncology Roundtable MOASC News/ MOASC Programs
-
LIVE, SATURDAY! MOASC’s Oncology Summit & Research Symposium MOASC News/ MOASC Programs
-
Dr. Lorna Breen Health Care Provider Protection Act signed into law National News
-
End the Pharmacy Benefit Manager (PBM) Safe Harbor National News
|
|
MOASC Programs - Save the Dates - All Times are Pacific
|
|
LIVE! MOASC’s 7th Annual Oncology Summit & Research Symposium at the Hyatt Regency in Huntington Beach. On March 26, 2022, this LIVE Meeting will follow a multi-tumor approach with nationally recognized speakers, which will review personalized cancer care and current clinical trials in Breast, Gastrointestinal, Genitourinary, Lung, CAR-T/Transplant and Myeloma. This will be a great opportunity to learn from experts and network with colleagues.
Pharmaceutical representatives, if you have any questions contact Wendy Alfaro at moasc@moasc.org.
|
|
Don’t miss this Thursday’s MOASC Targeted Oncology Roundtable. The Virtual Case-Based Roundtable Meeting is a collaborative, small-group meeting designed around case-based clinical profiles and peer-dialogue led by an expert physician. This session offers practicing oncologists the perfect opportunity to sharpen their skills and expertise in treatment strategies. Attendees are paid $500 of compensation by Healthcare Research Analytics® for their attendance, participation & completion of the post-event HRA survey.
Program 1, is open to, and intended for, oncologists treating Myeloproliferative Neoplasms: Myelofibrosis and Polycythemia vera. Angela Fleischman, M.D. (UC Irvine) will moderate this program on March 24, 7pm-8:30pm.
|
|
MOASC presents, “Disparities in Clinical Trials,” clinical webinar, Thursday, April 7, 5:30pm PDT. This presentation will provide a high level overview of clinical trials, discuss disparities in breast cancer, and a summary of initiatives to better engage with patients. Presented by: Adeline Wang, MD, PhD and Venky Kashi, PhD. Sponsored by Pfizer.
|
|
Career News
Sign up now to receive the MOASC Job Flash™! Please activate your new job alert.
|
|
MOASC Clinical Trial Database is on the MOASC website at www.moasc.org
|
|
Employees are entitled to up to 80 hours of 2022 COVID-19 related paid sick leave from January 1, 2022 through September 30, 2022. This is for covered employees in the public or private sectors who work for employers with 26 or more employees.
Beginning April 1, 2022, UnitedHealthcare will no longer mail prior authorization and clinical decision letters, for most* UnitedHealthcare plans in the West region. This includes letters requesting additional information, approvals and denials. Instead, you’ll be able to view them 24/7 through either the UnitedHealthcare Provider Portal or an Application Programming Interface (API). This change affects network medical health care professionals (primary and ancillary) and facilities in California and the western region.
|
|
Colorectal Cancer Screening Saves Lives. Colorectal cancer affects men and women of all racial and ethnic groups, and risk increases with age. During Colorectal Cancer Awareness Month, encourage screening to help find this cancer early, when treatment is most effective. Medicare covers colorectal cancer screening, and your patients pay nothing if you accept assignment.
|
|
Effective January 1, 2022, CMS has issued updated guidance on evaluation and management services that qualify as split or shared services by two providers who are in the same group.
|
|
Starting April 25, 2022, all codes requiring an invoice price including but not limited to A9500 will deny as unprocessable if not submitted with a clear total invoice price.
|
|
Complying with Medicare Signature Requirements — Revised. The Medicare Claims Review Contractor reviews documentation to ensure it meets Medicare’s signature requirements, like signed and dated medical records. If your entries are not signed and dated, they may deny associated claims.
|
|
Quarterly Update to the NCCI PTP Edits, Version 28.1, Effective April 1, 2022. CR 12567 is the quarterly update to the National Correct Coding Initiative (NCCI) Procedure-to-Procedure (PTP) edits. The attached recurring update notification applies to publication 100-04, chapter 23, section 20.9. Make sure your billing staff knows about these changes.
|
|
April 2022 Quarterly ASP Medicare Part B Drug Pricing Files and Revisions to Prior Quarterly Pricing Files
CR 12559 tells you that CMS will supply the contractors with the Average Sales Price (ASP) and Not Otherwise Classified (NOC) drug pricing files for Medicare Part B drugs on a quarterly basis. Make sure your billing staff knows about these changes.
|
|
March 29, 2022 Medicare Secondary Payer (MSP) Part B Billing webinar. This webinar is intended for Part B providers and will include: • Part B Billing Options, Payments and Calculations • Overpayment Process • Forms and Noridian Medicare Portal (NMP) • Avoiding Delays • Resources.
|
|
March 30, 2022 - Telehealth Provider Enrolling in Medicare
Learn telehealth regulations and how to enroll in Medicare as a provider or supplier. Learn about eligible providers, originating sites, distant site practitioners, and what type of equipment for communication is necessary for compliance.
|
|
April 6, 2022, Physician Assistants and Practice Ownership Webinar includes: Physician Assistant Ownership Interest, Physician Assistant Enrolling in Medicare, Physician Assistant Enrolling as a Sole Proprietor, CMS 855I Initial Enrollment as a Physician Assistant, CMS 855 B Initial Enrollment as a Sole Owner - Physician Assistant, Electronic Funds Transfer Agreement, and Physician Assistant accepting reassignment as the employer.
|
|
April 2022 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing Files and Revisions to Prior Quarterly Pricing Files. |
|
The Dr. Lorna Breen Health Care Provider Protection Act, which funds efforts to support the mental health of health care workers, has been signed into law by President Biden. The law, which was named after a doctor who died by suicide during the first year of the pandemic, will allocate up to $135 million to fund mental health education and awareness initiatives intended to reduce stigma, provide training and encourage health care professionals to seek care.
President Biden announced the next steps for the revived Cancer Moonshot program aimed at halving the number of cancer deaths in the next 25 years and enhancing quality of life for those who have cancer or have recovered from the disease. Steps include efforts by the FDA to cut morbidity and mortality associated with tobacco use, expansion of a Defense Department clinical research program and a rule that will consider "presumptive service connection" for several rare respiratory cancers for some veterans.
|
|
Tell the Federal Trade Commission to end the Pharmacy Benefit Manager (PBM) Safe Harbor that increases prescription drug costs. Pharmacy benefit managers have long been protected by a legal “safe harbor” that allows them to charge drug manufacturers exorbitant fees to access the millions of patient lives whose drug benefits are managed by PBMs. These excessive fees are problematic because they raise the cost of drugs. With the safe harbor protecting this business practice, a “pay-to-play” scenario has emerged between drug manufacturers and these PBM middlemen that distorts free-market competition and promotes increased drug costs that are passed on to patients.
|
|
The NIH has launched a program to offer molecular characterization of childhood cancers. |
|
Please complete the form on the following link to join our Clinician Volunteer Corps to work in tandem with the American Cancer Society’s National Cancer Information Center team members in fielding inquiries from patients, family members, and clinicians in Eastern Europe. Thank you for considering this important opportunity to assist cancer patients during this extremely difficult time.
|
|
Patients with limited health literacy or low socioeconomic status who experienced a diagnostic error were most likely to cite poor communication with their health provider as a contributing factor, an AHRQ-funded study published in BMJ Quality and Safety has found. Researchers surveyed nearly 600 people who reported experiencing a medical error caused by a delayed, missed or incorrect diagnosis. About two-thirds of the respondents (381 respondents) met the criteria for low health literacy or low socioeconomic status. The most common contributing factor reported by 69 percent of the participants was “healthcare providers not listening to the patient.” Other factors noted included teams of providers without a clear leader, no qualified translator or provider who spoke the patient’s language, inability to keep follow-up appointments and inability to pay for necessary care. The authors identified access to interpreter services as a “diagnostic safety imperative,” among others.
|
|
Affiliate Association News |
|
Applications for ANCO’s Travel Awards to Fellows and Young Clinicians to support attendance at the ASCO Annual Meeting, ASH Annual Meeting, or other national oncology meeting in 2022 are now being accepted. Application deadline has been extended to April 14.
|
|
AstraZeneca announced that the FDA approved a new indication for LYNPARZA® (olaparib) for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. FDA approval was based on the results from the OlympiA phase 3 trial, which was presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine.
|
|
Bristol Myers Squibb's lymphocyte-activation gene 3 inhibitor Opdualag, or relatlimab, was approved by the FDA in combination with Opdivo to treat advanced melanoma. The company is also testing the combination for other cancers.
|
|
Foundation Medicine announced that FDA approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer. |
|
Merck announced that the FDA approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
